ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Curcumin: The All In One Solution, Part 2

What Are the Benefits of Vitamin K2?

Vitamin D deficiency + high fat diet = metabolic syndrome

Why You Should Take Your Apple Cider Vinegar at Night

Use Burdock Oil to Promote Healthy Hair Growth

AMA journal associates iron deficiency with hearing loss

Meet Your Weight Loss Goals

People with forms of early-onset Parkinson's disease may benefit from boosting niacin in diet, resea...

Lutein linked to preservation of crystallized intelligence

Zinc eaten at levels found in biofortified crops reduces 'wear and tear' on DNA

 
Print Page
Email Article

FDA Approves Irritable Bowel Syndrome Treatment For Women

  [ 32 votes ]   [ Discuss This Article ]
By FDA TALK PAPER • www.ProHealth.com • February 9, 2000


The FDA today approved alosetron hydrochloride, a new medication to treat irritable bowel syndrome (IBS) in women whose predominant bowel symptom is diarrhea. The following may be used to answer questions.

IBS is a functional abnormality of the gastrointestinal tract that is estimated to affect up to 15% of the US population. People with this condition experience chronic or recurrent abdominal pain, irregular bowel movements including diarrhea and constipation, and the sudden, urgent need to go to the bathroom. It is three times more common in women than men.

Like existing IBS therapies, alosetron treats the symptoms associated with the syndrome. Although how the drug works is not completely understood, alosetron slows intestinal movement and may provide relief by targeting the underlying neurological activity associated with the condition.

FDA based its approval on the results of two 12-week double-blinded, placebo-controlled clinical trials. A total of 1273 non-constipated women, who met specific pain and stool consistency criteria, were enrolled.

In each study, alosetron was significantly more effective than placebo in providing relief from IBS pain and discomfort and in reducing the percentage of days with urgency. Treatment with alosetron also resulted in firmer stools and a significant decrease in stool frequency.
Significant improvement of symptoms typically occurred within the first weeks of alosetron treatment and persisted throughout the 12 weeks of the studies. Upon discontinuance of alosetron, symptoms returned.

The most frequent adverse event reported by study participants taking alosetron was constipation, which in many cases required interruption or discontinuation of treatment. Occurrences of constipation were generally mild to moderate in intensity and transient in nature. The drug's label recommends managing this adverse effect by temporarily stopping drug treatment and giving customary care, including laxatives and fiber.

In addition, four study patients taking alosetron developed acute colitis, a potentially serious inflammation of the large intestine. This condition resolved without serious consequences when the drug was discontinued. Although a causal relationship between the drug and this adverse effect has not been established, further assessment is underway.

Health care providers are advised to interrupt treatment immediately and to evaluate promptly patients who have symptoms of acute colitis such as bloody diarrhea and sudden, significant worsening of abdominal pain. The FDA encourages health care providers to report any such cases to FDA's MedWatch program by calling 1-888-INFO-FDA or by logging onto FDA's web page, www.fda.gov/medwatch.

Alosetron has not been shown to be safe and effective in men, and its use in men is not recommended.

Today's decision follows a November 1999 recommendation for approval by FDA's Gastrointestinal Drugs Advisory Committee.

Alosetron will be marketed as Lotronex by GlaxoWellcome of Research Triangle Park, NC.

Source: FDA TALK PAPER, February 9, 2000. Food and Drug Administration, U.S. Department of Health and Human Services, Public Health Service 5600 Fishers Lane Rockville, MD 20857.



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Mitochondria Ignite™ with NT Factor® Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Coenzyme Q10 - The Energy Maker Coenzyme Q10 - The Energy Maker
Herbal Rescue for High Blood Sugar Herbal Rescue for High Blood Sugar
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map